[1]陈立波.钠/碘同向转运体与放射性碘治疗[J].国际放射医学核医学杂志,2001,25(6):258-261.
　CHEN Li-bo.The sodium/iodide symporter and radioiodide therapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2001,25(6):258-261.
点击复制

钠/碘同向转运体与放射性碘治疗(/HTML)
分享到：

《国际放射医学核医学杂志》[ISSN:1673-4114/CN:12-1381/R]

卷:
25
期数:
2001年第6期
页码:
258-261
栏目:
综述
出版日期:
1900-01-01

文章信息/Info

Title:
The sodium/iodide symporter and radioiodide therapy
作者:
陈立波
200233 上海, 上海市第六人民医院核医学科
Author(s):
CHEN Li-bo
Nuclear Medicine Department of Shanghai Sixth People’s Hospital, Shanghai 200233, China
关键词:
钠/碘同向转运体; 放射性碘治疗; 甲状腺癌; 乳腺癌; 前列腺癌
Keywords:
sodium/iodide sympertor; radioiodide therapy; thyroid cancer; breast cancer; prostate cancer
分类号:
R817.5
摘要:
钠/碘同向转运体(NIS)是一种调节甲状腺及其他组织碘转运活性的膜蛋白。NIS在甲状腺的病理生理中发挥着关键性作用,它实现了甲状腺组织摄取碘并进行甲状腺激素的生物合成,实现了甲状腺功能亢进和分化型甲状腺癌的显像诊断和放射性碘治疗。近年来,对NIS的进一步分子学研究表明,NIS有可能对甲状腺及非甲状腺肿瘤的诊断和放射性碘治疗产生更加深远的影响。
Abstract:
The sodium/iodide symporter (NIS) is an intrinsic membrane protein that mediates the active transport of iodide into the thyroid and other tissues. NIS plays key roles in thyroid pathophysiology as the route by which iodide reaches the gland for thyroid hormone biosynthesis and as a means for diagnostic scintigraphic imaging and for radioiodide therapy in hyperthyroidism and thyoid cancer. The continued molecular analysis of NIS clearly holds the potential of an even greater impact on the diagnosis and radioiodide treatment of cancer, both in thyroid and beyond.

参考文献/References:

[1] Dai G, Levy O, Carrasco N.Cloning and characterization of the thyroid iodide transporter[J].Nature, 1996, 379:458-460.
[2] Smanik PA, Liu Q, Furminger TL, et al.Cloning of the human sodium iodide sympertor[J].Biochem Biophys Res Commun, 1996, 226:339-345.
[3] Schmutzler C, Kohrel J.Implications of the molecular characterization of the sodium-iodide symporter (NIS)[J].Exp Cline Endocrinol Diabetes, 1998, 106(3):S1-S10.
[4] Kotani T, Ogata Y, Yamamoto I, et al.Characterization of gastric Na+/I- symporter of the rat[J].Clin Immunl Immunopathol, 1998, 89(3):271-278.
[5] Ajjan RA, Kamaruddin NA, Crisp M, et al.Regulation and tissue distribution of the human sodium iodide symporter gene[J].Cline endorine Oxf, 1998, 49(4):517-523.
[6] Saito T, Endo T, Kawaguchi A, et al.Increased expression of the in cultured human thyroid cells exposed to thyotropin and in Graves’ thyroid tissue[J].J Clin Endocrinol Metab, 1997, 82(10):3331-3336.
[7] Kogai T, Endo T.Regulation by thyroid stimulating hormone of sodium/iodide symporter gene expression and protein levels in FRTL-5 cells[J].Endocrinology, 1997, 138(6):2227-2232.
[8] Suzuki K, Mori A, Lavaroni S, et al.Thyroglobulin regulates follicular function and heterogeneity by suppressing thyroid specific gene exprssion[J].Biochimie, 1999, 81(4):329-340.
[9] Schmutzler C, Winzer R, Meissner-Wergl J, et al.Retonic acid increases sodium/iodide symporter mRNA levels in human thyroid cancer cell lines and suppresses expression of functional symporter in nontransformed FRTL-5 rat thyroid cells[J].Biochem Biophys Res Commun, 1998, 246:562-568.
[10] Harri N, Endo T, Ohmori M, et al.Extracellular adenosine increases Na+/I- symporter gene expression in rat thyroid FRTL-5 cells[J].Mol Cell Endocrinol, 1999, 157(1-2):31-39.
[11] Pohkenz J, Refetoff S.Mutations in the sodium-iodide symporter (NIS) gene as a cause for iodide transport defects and congenital hypothyroidism[J].Biochimie, 1999, 81(5):469-476.
[12] Mazzaferri EL.Carcinoma of follicular epithelium:radioiodine and other treatments and outcomes[A].Braverman LE, Utiger RD, eds.The thyroid:a fundamental and clinical text[C].7th Ed.Philadelphia:Lippincott Raven, 922-945.
[13] Smanik PA, Ryu K Y, Theil KS, et al.1997 Expression, exon intron organization, and chromosome mapping of the human sodium iodide symporter[J].Endocrinology, 1997, 138:3555-3558.
[14] Park H J, Kim JY, Park KY, et al.Expressions of human sodium iodide symporter mRNA in primary and metastatic papillary thyroid carcinomas[J].Thriod, 2000, 10:211-217.
[15] Caillous B, Troalen F, Baudin E, et al.Na+/I- symporter distribution in human thyroid tissues:an immunohistochemical study[J].Clin Endocrinol Metab.1998, 83:4102-4106.
[16] Schmutzler C, Winzer R, Meissner-Weigl J, et al.Retinoic acid increases sodium/iodide symporter mRNA levels in human thyroid cancer cell lines and suppresses expression of functional sympporter in nontransformed FRTL-5 rat thyroid cells[J].Biochem Biophys Res Commun, 1997, 240:832-838.
[17] Simon D, Koehrle J, Reiners C, et al.Redifferentiation therapy with retinoids:therapeutic option for advanced follicular and papillary carcinoma[J].Wold J Surg, 1998, 22:569-574.
[18] Venkataraman GM, Yatin M, Marcinek R, et al.Restoration of iodide symporter in dedifferntiated thyroid carcinoma:Relaionship to human Na+/I- symporter gene methylation status[J].J Clin Endocrine Metab, 1999, 84:2449-2457.
[19] Eskin BA, Parker JA, Bassett JG, et al.Human breast uptake of radioactive iodine[J].Obstet Gynecol, 1974, 44:398-402.
[20] Eskin BA.Iodine and mammary cancer[J].Adv Exp Med Biol, 1977, 91:293-304.
[21] Cancroft ET, Goldsmith SJ.99Tcm-pertchnetate scintigraphy as an aid in the diagnosis of breast masses[J].Radiology, 1973, 106:441-444.
[22] Tazebay UH, Wapnir IL, Levy O, et al.The mammary gland iodide transporter is expressed during lactation and in breast cancer[J].Nat Med, 2000, 6:871-878.
[23] Kogai T, Schultz J, Johnson L, et al.Retinoic acid induces sodium/iodide symporter gene expression and radioiodide uptake in the MCF-7 breast cancer cell line[J].Proc Natl Acad Sci USA, 2000, 97:8519-8524.
[24] Cho JY, Xing S, Liu X, et al.Expression and activity of human Na+/I- symporter in human glioma cells by adenovirus-mediated gene delivery[J].Gene Ther, 2000, 7:740-749.
[25] Mandell RB, Mandell LZ, Link CJ.Radioisotope concentrator gene therapy using the sodium/iodide symporter gene[J].Cancer Res, 1999, 59:661-668.
[26] Boland A, Ricard M, Opolon P, et al.Adenovirusmediated transfer of the sodium/iodide symporter gene into tumors for a targeted radio-therapy[J].Cancer Res, 2000, 60:3484-3492.
[27] Nakamato Y, Saga T, Misaki T, et al.Establishment and characterization of a breast cancer cell line expressing Na+/I- symporter for radioiodide concentrator gene therapy[J].J Nucl Med, 2000, 41:1898-1904.
[28] Spitzweg C, Zhang S, Bergert ER, et al.Prostate-specific antigen (PSA) promoter-driven androgen-in-ducible expression of sodium/iodide symporter in prostate cancer cell lines[J].Cancer Res, 1999, 59:2136-2141.
[29] Spitzweg C, O’Connor MK, Bergert ER, et al.Treatment of prostate cancer by radioiodine therapy after tissues-specific expression of sodium/iodide symporter[J].Cancer Res, 2000, 60:6526-6530.
[30] Bogazzi F, Bartalena L, Brogiomi S, et al.Comparison of radoiodine with radoiodeme plus lithium in the treatmnt of Graves’ hyperthyroidism[J].J Clin Endocrinol Metab, 1999, 84:499-503.

相似文献/References:

[1]欧阳萌.131I治疗儿童及青少年Graves病[J].国际放射医学核医学杂志,2004,28(2):70.
　OU Yang-meng.131I therapy of Graves’ disease in childhood and adolescence[J].International Journal of Radiation Medicine and Nuclear Medicine,2004,28(6):70.
[2]张一帆,李彪.钠/碘同向转运体在甲状腺癌131I治疗中的应用[J].国际放射医学核医学杂志,2004,28(6):249.
　ZHANG Yi-fan,LI Biao.Application of sodium/iodide symporter gene in thyroid cancer for radiotherapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2004,28(6):249.
[3]李倩.钠/碘转运体的临床实用价值[J].国际放射医学核医学杂志,2003,27(2):56.
　LI Qian.Clinical value of sodium iodide symporter[J].International Journal of Radiation Medicine and Nuclear Medicine,2003,27(6):56.
[4]葛素娟.甲状腺癌术后131I治疗[J].国际放射医学核医学杂志,2002,26(4):163.
　GE Su-juan.131I therapy of thyroid cancer after surgery[J].International Journal of Radiation Medicine and Nuclear Medicine,2002,26(6):163.
[5]邢岩.TPO基因及其应用研究[J].国际放射医学核医学杂志,2002,26(6):248.
　XING Yan.The research and application of TPO’s gene[J].International Journal of Radiation Medicine and Nuclear Medicine,2002,26(6):248.
[6]罗全勇.基因转染诱导核素靶向治疗的实验研究[J].国际放射医学核医学杂志,2001,25(2):60.
　LUO Quan-yong.Inducement of radionuclides targeting therapy by gene transfection[J].International Journal of Radiation Medicine and Nuclear Medicine,2001,25(6):60.
[7]丁昊,叶斌,雷勇.增强DTC病灶摄取131I功能的措施[J].国际放射医学核医学杂志,2001,25(4):145.
　DING Hao,YIE Bin,LEI Yong.The augmentation of 131I uptake of DTC[J].International Journal of Radiation Medicine and Nuclear Medicine,2001,25(6):145.
[8]柳卫,张满达,王铁生.钠/碘同向转运体[J].国际放射医学核医学杂志,2001,25(2):49.
　LIU Wei.The sodium/iodide symporter[J].International Journal of Radiation Medicine and Nuclear Medicine,2001,25(6):49.
[9]黄蕤.NIS基因转染肿瘤细胞介导131I治疗[J].国际放射医学核医学杂志,2001,25(5):204.
　HUANG Rui.Transfection of the Na+/I- symporter gene into tumors for radioiodide therapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2001,25(6):204.

备注/Memo

备注/Memo:
收稿日期:2001-10-25。
作者简介:陈立波(1973-),男,江苏盐城人,上海市第六人民医院核医学科住院医师,苏州大学临床核医学专业硕士研究生,研究方向:核素治疗。
更新日期/Last Update: 1900-01-01